Medicines for Ireland (MFI), the Irish pharmaceutical trade association, has welcomed the coordinated approach agreed by European Union leaders for the procurement of medicines, medical
The Government continues to overspend millions on expensive big brand medicines despite the availability of more affordable, equally effective generic and biosimilar alternatives. State losing
[vc_row][vc_column][vc_icon icon=”fa fa-file-pdf-o” icon_color=”color-188384″ size=”fa-5x” title=”Generics@5 Report” link=”url:http%3A%2F%2Fwww.medicinesforireland.ie%2Fwp-content%2Fuploads%2F2017%2F06%2FMedicines_for_Ireland-Generics%405.pdf||target:%20_blank|” link_text=”View report”]July 2018[/vc_icon][vc_column_text]A representative body for Ireland’s largest medicine suppliers has warned that medicine costs for the
As healthcare stakeholders gather together today (Monday) as part of a Health Products Regulatory Authority (HPRA) initiative to develop solutions to the growing problem of
A leading Irish pharma body, Medicines for Ireland, which represents the generics industry here, with members such as Mylan, Teva, Pinewood, Clonmel Healthcare, met with
Article by Charlie Taylor Irish Times, Monday 21 May 2018 Biosimilars are medicines that have no clinically meaningful difference from the original patented biologic medication
Medicines for Ireland has announced the appointment of Mylan Ireland Country Manager, Owen McKeon, as new chairperson of the organisation, taking over from Sandra Gannon
THE Government spent €57.5million on three name brand drugs despite cheaper, equally effective alternatives available. The HSE has forked out the cash this year on
Medicines for Ireland, the representative association for generic and biosimilar suppliers in Ireland, has cautioned that a promised new National Biosimilar Policy may lead to
Leading European experts will discuss existing policy and debate reforms, including the wider availability of adrenaline auto-injectors (AAIs) in European public spaces
We are committed to working with key stakeholders to affect real change and reforms that ensure Irish patients receive the best medical treatment in the most affordable way.
